GlassScriptPhysician profile
Michael Y Ashigbi
NPI 1649275355
$2,127.18
in general payments reported to CMS, 2019-2025
21 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $349 · 2021: $90.38 · 2022: $34.99 · 2023: $483 · 2024: $523 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107 · Education: $63.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,107.09 |
| Education | $63.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $332.35 | 2022-2023 | Myrisk |
| Astrazeneca Pharmaceuticals LP | $288.38 | 2019-2025 | Imfinzi, Enhertu |
| Abbvie INC. | $275.58 | 2024-2025 | |
| Celgene Corporation | $208.24 | 2019-2020 | |
| Genentech USA, INC. | $152.77 | 2019-2024 | Tecentriq |
| Takeda Pharmaceuticals U.S.A., INC. | $145.97 | 2019-2020 | |
| Janssen Biotech, INC. | $128.79 | 2021-2024 | Tecvayli, Darzalex |
| Pharmacyclics LLC, An Abbvie Company | $116.97 | 2021-2023 | Epkinly, Imbruvica |
| Daiichi Sankyo INC. | $113.09 | 2020 | |
| Novartis Pharmaceuticals Corporation | $103.99 | 2021-2024 | |
| Gilead Sciences, INC. | $50.59 | 2019-2021 | |
| Exelixis INC. | $42.42 | 2019 | |
| Sun Pharmaceutical Industries INC. | $22.72 | 2023 | Odomzo, Yonsa |
| Eagle Pharmaceuticals, INC. | $22.72 | 2020 | |
| Array Biopharma INC | $22.21 | 2024 | Xalkori, Lorbrena, Braftovi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $22.10 | 2019 | |
| Pfizer INC. | $20.77 | 2024 | |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Glaxosmithkline, LLC. | $18.29 | 2021 | |
| Karyopharm Therapeutics INC. | $14.91 | 2021 | |
| Clovis Oncology, INC. | $4.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ashigbi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.